18 December 2020
How come that first generation of SARS-CoV-2 vaccines may not provide high-level, long-term protection?
How do the vaccines compare?
What are the advantages of the second generation of the COVID-19 vaccine?
Are current vaccines effective and for how long?
How many shots do we need?
Our CEO, Dr. Vladimir Cmiljanovic, answered these and many more questions about the challenges of developing a safe and effective SARS-CoV-2 vaccine in RocketVax for PRVA TV:
In the process of developing our vaccine against SARS-CoV-2, our experts in RocketVax use coronavirus-based vectors that carry all the coronavirus’s immunogenic features but cannot reproduce, making the particles non-infectious.
A digital DNA design platform ensures the novel vaccine vectors’ easy design and streamlined production. Utilizing highly sophisticated algorithms, we have generated custom-designed synthetic viral genomes packed into attenuated yet authentic virus particles.
These particles can be continuously produced in a highly controlled process using well-characterized cell lines.
22 April 2021
“There is light at the end of the tunnel. Progress is being made in vaccines against SARS-CoV-2, if somewhat slowly, particularly in Switzerland. They promise a return to normality, though they are not without setbacks. The vector vaccines developed by AstraZeneca and Johnson & Johnson are under fire following cases of thrombosis in younger women. […]
21 April 2021
Dr. Vladimir Cmiljanovic, CEO of RocketVax, gave an interview to Swiss SRF 1 radio about the progress of RVX-13 – a second-generation SARS-CoV-2 vaccine: Source: SRF 1 Radio The most important differences between RVX-13, RocketVax’s SARS-CoV-2 vaccine, and the first-generation vaccines are as follows: 1. RVX-13 induces a comprehensive activation of the immune system. Unlike […]
20 April 2021
When the ongoing coronavirus pandemic broke out at the start of 2020, Swiss Rockets AG set itself the challenge of manufacturing a vaccine that activates multiple lines of immune system defense to combat SARS-CoV-2 most effectively. To achieve this mission, it founded the Basel-based subsidiary RocketVax AG in the summer of 2020. To start working […]
09 April 2021
CEO of RocketVax, Dr. Vladimir Cmiljanovic, explains for Kanal 5 TV Macedonia his opinion on how China has managed to control the pandemic rapidly and effectively. During the interview, Dr. Cmiljanovic also talked about the development of the second-generation SARS-CoV-2 vaccine, RVX-13, that will provide long-lasting immunity. “The first reason is that the socialist system […]
16 March 2021
CEO of RocketVax, Dr. Vladimir Cmiljanovic, gave an interview about the development of the second-generation SARS-CoV-2 vaccine for RTS (Serbian Broadcasting Corporation). “The first-generation vaccines are focused on one of the virus’s proteins – the so-called spike protein. They train our immune system by exposing the coronavirus spike protein to our immune cells. The so […]